ResearchMoz added Latest Research Report titled ” PharmaPoint: Ulcerative Colitis – Global Drug Forecast and Market Analysis to 2022 ” to it’s Large Report database.
During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada.
Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.
Overall, major barriers to the growth of the UC market include
Remicade and Humira losing patent protection in the midforecast
Austerity measures favoring generic prescribing
Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=195531
In 2012, GlobalData estimates that the global UC market reached $4.2 billion across the 10 healthcare markets covered in our forecast: the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China, and India. By the end of the forecast period, in 2022, sales across these markets will grow steadily to reach $6.6 billion, representing a Compound Annual Growth Rate (CAGR) of 4.8% over the 10year timeframe.
Key Questions Answered
- How will the UC market (sales and patient numbers) evolve over the 10year forecast period from 2012 to 2022?
- Which brands and specific drug classes did physicians select for their UC patients in 2012 and how do they foresee their prescribing behavior evolving over the next five years?
- How will the launch of latestage pipeline therapies such as Entyvio and Kappaproct shape the future treatment landscape?
- What are the remaining unmet needs and opportunities for drug developers within the UC market?
Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html
Table of Content
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 29
3.2 Symptoms 30
3.2.1 Quality of Life 31
4 Epidemiology 32
4.1 Disease Background 32
4.2 Risk Factors and Comorbidities 33
4.2.1 Being Caucasian and Jewish can increase the risk of UC by almost 37 times 34
4.2.2 A family history of UC in first-degree relatives can increase the risk of the disease by almost three-fold 34
4.2.3 Current smokers have a lower risk of developing UC than former smokers or never smokers 35
ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY, United States – 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Follow me on Blogger at: http://healthcare-research-report.blogspot.in/